← Back to Search

Corticosteroid

IRD Regimen for Multiple Myeloma

Phase 2
Waitlist Available
Led By Ravi Vij, M.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2
Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid REMS program material. This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide. Women of childbearing potential must also agree to ongoing pregnancy testing
Must not have
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Tandem autologous transplantation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days after the completion of maintenance treatment (estimated to be day 1125 of maintenance treatment)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment for people who have had stem cell transplants, to see if it can help prolong the time they are disease-free.

Who is the study for?
Adults aged 18-70 with symptomatic multiple myeloma, who've had initial therapy and are within 2-16 months of starting it. They must have good organ function, not be pregnant or breastfeeding, agree to contraception if applicable, and follow REMS program requirements for lenalidomide. Exclusions include other active cancers needing treatment, recent major surgery or serious infections, certain heart conditions, severe neuropathy among others.
What is being tested?
The trial is testing the IRD regimen (Ixazomib, Lenalidomide, Dexamethasone) after stem cell transplantation in multiple myeloma patients. Post four cycles of IRD treatment participants will randomly receive maintenance therapy with either Ixazomib or Lenalidomide to see which helps keep the disease at bay longer.
What are the potential side effects?
Possible side effects include low blood counts leading to increased infection risk; nerve damage causing pain or numbness; digestive issues like nausea and diarrhea; rash; fatigue; liver problems indicated by abnormal tests; and potential blood clots due to lenalidomide.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and perform daily activities.
Select...
I am following strict birth control and pregnancy testing as required if I can have children.
Select...
I am between 18 and 70 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I am scheduled for or have had two stem cell transplants using my own cells.
Select...
I do not have severe heart issues or uncontrolled blood pressure problems.
Select...
I have an active hepatitis infection or am HIV positive.
Select...
I do not have any stomach or intestine problems that could affect how a medicine is absorbed.
Select...
I have had plasma cell leukemia or myeloma that spread to the brain.
Select...
I have severe nerve damage in my hands or feet, or moderate with pain.
Select...
I have not had major surgery in the last 2 weeks.
Select...
I am not receiving treatment for any cancer other than multiple myeloma or secondary amyloidosis.
Select...
I have had an organ transplant and am on immunosuppressive drugs.
Select...
I have not needed antibiotics for a serious infection in the last 2 weeks.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days after the completion of maintenance treatment (estimated to be day 1125 of maintenance treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after the completion of maintenance treatment (estimated to be day 1125 of maintenance treatment) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Improvement in Minimal Residual Disease (MRD)
Secondary study objectives
Association of Overall Survival With MRD-negativity
Association of Overall Survival With MRD-positivity
Association of Progression-free Survival With MRD-negativity
+10 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Maintenance Arm 2: LenalidomideExperimental Treatment1 Intervention
Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
Group II: Maintenance Arm 1: IxazomibExperimental Treatment1 Intervention
Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
Group III: Consolidation: Ixazomib, Lenalidomide, & DexamethasoneExperimental Treatment3 Interventions
Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, \& dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 15 mg of lenalidomide will be administered on daily on Days 1-21.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ixazomib
2017
Completed Phase 4
~3510
Lenalidomide
2005
Completed Phase 3
~2240
Dexamethasone
2007
Completed Phase 4
~2650

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,989 Previous Clinical Trials
2,295,582 Total Patients Enrolled
37 Trials studying Multiple Myeloma
2,021 Patients Enrolled for Multiple Myeloma
Millennium Pharmaceuticals, Inc.Industry Sponsor
404 Previous Clinical Trials
46,672 Total Patients Enrolled
82 Trials studying Multiple Myeloma
9,826 Patients Enrolled for Multiple Myeloma
Multiple Myeloma Research ConsortiumNETWORK
20 Previous Clinical Trials
1,110 Total Patients Enrolled
19 Trials studying Multiple Myeloma
1,057 Patients Enrolled for Multiple Myeloma

Media Library

Dexamethasone (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT02253316 — Phase 2
Multiple Myeloma Research Study Groups: Consolidation: Ixazomib, Lenalidomide, & Dexamethasone, Maintenance Arm 1: Ixazomib, Maintenance Arm 2: Lenalidomide
Multiple Myeloma Clinical Trial 2023: Dexamethasone Highlights & Side Effects. Trial Name: NCT02253316 — Phase 2
Dexamethasone (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02253316 — Phase 2
~22 spots leftby Nov 2025